These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22570295)

  • 41. Safety and efficacy of rapid (1,000 mg in 1 hr) intravenous iron dextran for treatment of maternal iron deficient anemia of pregnancy.
    Wong L; Smith S; Gilstrop M; Derman R; Auerbach S; London N; Lenowitz S; Bahrain H; McClintock J; Auerbach M
    Am J Hematol; 2016 Jun; 91(6):590-3. PubMed ID: 26971581
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Iron utilization after iron dextran administration for iron deficiency in patients with dialysis-associated anemia: a prospective analysis and comparison of two agents.
    Roe DJ; Harford AM; Zager PG; Wiltbank TB; Kirlin L; Della Valle AM; Van Wyck DB
    Am J Kidney Dis; 1996 Dec; 28(6):855-60. PubMed ID: 8957037
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale.
    Macdougall IC; Dahl NV; Bernard K; Li Z; Batycky A; Strauss WE
    BMC Nephrol; 2017 Apr; 18(1):117. PubMed ID: 28372549
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients.
    Sepandj F; Jindal K; West M; Hirsch D
    Nephrol Dial Transplant; 1996 Feb; 11(2):319-22. PubMed ID: 8671786
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Maintaining iron balance with total-dose infusion of intravenous iron dextran.
    Case G
    ANNA J; 1998 Feb; 25(1):65-8. PubMed ID: 9543911
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety aspects of parenteral iron in patients with end-stage renal disease.
    Sunder-Plassmann G; Hörl WH
    Drug Saf; 1997 Oct; 17(4):241-50. PubMed ID: 9352960
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of iron deficiency anemia with intravenous iron preparations.
    Akarsu S; Taskin E; Yilmaz E; Yilmaz H; Kilic M; Aygun AD
    Acta Haematol; 2006; 116(1):51-7. PubMed ID: 16809890
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Parenteral iron supplementation.
    Kumpf VJ
    Nutr Clin Pract; 1996 Aug; 11(4):139-46. PubMed ID: 9070014
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The utility of zinc protoporphyrin for predicting the need for intravenous iron therapy in hemodialysis patients.
    Fishbane S; Lynn RI
    Am J Kidney Dis; 1995 Mar; 25(3):426-32. PubMed ID: 7872320
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Addressing patient concerns about intravenous iron therapy.
    Robbins KC
    Nephrol Nurs J; 2003 Apr; 30(2):220-4, 258. PubMed ID: 12737000
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravenous iron dextran treatment in predialysis patients with chronic renal failure.
    Dahdah K; Patrie JT; Bolton WK
    Am J Kidney Dis; 2000 Oct; 36(4):775-82. PubMed ID: 11007680
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intravenous iron administration in a short-stay hospital setting.
    Peebles G; Fenwick S
    Nurs Stand; 2008 Aug 6-12; 22(48):35-41. PubMed ID: 18727354
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis.
    Susantitaphong P; Alqahtani F; Jaber BL
    Am J Nephrol; 2014; 39(2):130-41. PubMed ID: 24513913
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Parenteral iron therapy options.
    Silverstein SB; Rodgers GM
    Am J Hematol; 2004 May; 76(1):74-8. PubMed ID: 15114602
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Parenteral iron therapy: a single institution's experience over a 5-year period.
    Laman CA; Silverstein SB; Rodgers GM
    J Natl Compr Canc Netw; 2005 Nov; 3(6):791-5. PubMed ID: 16316614
    [TBL] [Abstract][Full Text] [Related]  

  • 56. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.
    Birgegård G; Henry D; Glaspy J; Chopra R; Thomsen LL; Auerbach M
    Pharmacotherapy; 2016 Apr; 36(4):402-14. PubMed ID: 26927900
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Update on intravenous iron choices.
    Larson DS; Coyne DW
    Curr Opin Nephrol Hypertens; 2014 Mar; 23(2):186-91. PubMed ID: 24401789
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial.
    Nissenson AR; Lindsay RM; Swan S; Seligman P; Strobos J
    Am J Kidney Dis; 1999 Mar; 33(3):471-82. PubMed ID: 10070911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.